1. Home
  2. AURA vs STTK Comparison

AURA vs STTK Comparison

Compare AURA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

HOLD

Current Price

$6.02

Market Cap

797.5M

Sector

Health Care

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.36

Market Cap

792.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AURA
STTK
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
797.5M
792.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
AURA
STTK
Price
$6.02
$6.36
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$20.00
$10.00
AVG Volume (30 Days)
616.2K
788.1K
Earning Date
05-08-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.73
$1.70
52 Week High
$9.54
$8.33

Technical Indicators

Market Signals
Indicator
AURA
STTK
Relative Strength Index (RSI) N/A 47.42
Support Level N/A $5.85
Resistance Level N/A $7.75
Average True Range (ATR) 0.00 0.29
MACD 0.00 0.01
Stochastic Oscillator 0.00 56.13

Price Performance

Historical Comparison
AURA
STTK

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: